kabutan

CHUGAI PHARMACEUTICAL CO., LTD.(4519) Summary

4519
TSE Prime
CHUGAI PHARMACEUTICAL CO., LTD.
8,252
JPY
-342
(-3.98%)
Jan 16, 3:30 pm JST
52.10
USD
Jan 16, 1:30 am EST
Result
PTS
outside of trading hours
8,240
Jan 16, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.18
Yield
3.03%
Margin Trading Ratio
5.77
Stock Price
Jan 16, 2026
Opening Jan 16, 9:03 am
8,348 JPY 52.64 USD
Previous Close Jan 15
8,594 JPY 54.20 USD
High Jan 16, 9:03 am
8,360 JPY 52.72 USD
Low Jan 16, 12:46 pm
8,204 JPY 51.76 USD
Volume
2,142,100
Trading Value
0.02T JPY 0.11B USD
VWAP
8271.1 JPY 52.22 USD
Minimum Trading Value
825,200 JPY 5,210 USD
Market Cap
13.86T JPY 0.09T USD
Number of Trades
6,048
Liquidity & Number of Trades
As of Jan 16, 2026
Liquidity
High
1-Year Average
6,967
1-Year High Aug 8, 2025
42,808
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 9, 2026 126,300 666,900 5.28
Dec 26, 2025 420,800 687,600 1.63
Dec 19, 2025 133,700 716,400 5.36
Dec 12, 2025 163,400 662,000 4.05
Dec 5, 2025 155,900 721,200 4.63
Company Profile
CHUGAI PHARMACEUTICAL CO., LTD. is a major pharmaceutical company. As a subsidiary of Roche, it has expanded its product line, including Tamiflu. The company's main focus is on anticancer drugs and rheumatoid arthritis treatments.
Sector
Pharmaceuticals
CHUGAI PHARMACEUTICAL CO., LTD. is a pharmaceutical company specializing in the research, development, manufacturing, and sales of pharmaceuticals, operating under the Swiss pharmaceutical giant Roche. In Japan, the company sells its own products through authorized dealers, while overseas it has sales bases in Europe, Taiwan, China, and other regions. Manufacturing is carried out at the company's domestic and international factories, as well as through contracted partners. As a member of the Roche Group, Chugai purchases some raw materials from Roche and distributes some products internationally through Roche's network. The company focuses on developing innovative drugs, particularly in the fields of cancer treatment and rheumatoid arthritis, while pursuing global business expansion.